EPID-19. CHANGES IN SURVIVAL OVER TIME FOR ALL PRIMARY BRAIN AND OTHER CNS TUMORS IN THE UNITED STATES. (14th November 2022)

• Record Type: Journal Article
• Authors: Edelson, Jacob; Waite, Kristin; Cioffi, Gino; Kruchko, Carol; Ostrom, Quinn; Barnholtz-Sloan, Jill
• Is Part Of: Neuro-oncology. Volume 24(2022)Supplement 7
• Page Start: vii113
• Page End: vii113
• Publication Date: 2022-11-14
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac209.429
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: BACKGROUND: Despite advances in cancer diagnosis and clinical care, survival for many primary brain and other central nervous system (CNS) tumors remain poor. This study performs a comprehensive survival analysis on these tumors. METHODS: Survival differences were determined utilizing the National Program of Cancer Registries Survival Analytic file for all primary brain and other CNS tumors. Overall survival and survival of the 5 most common histopathologies within specific age groups (children ages 0-14 years, adolescents, and young adults [AYA] ages 15-39 years, and older adults ages 40+ years) were determined. Overall survival was compared for three time periods: 2004-2007, 2008-2012, and 2013-2017. Kaplan-Meier and multivariable Cox proportional hazards models were used to generate median survival, hazard ratios (HR) and 95% confidence intervals (CI). Models were adjusted for sex, race/ethnicity, and treatment pattern. Malignant and non-malignant brain tumors were assessed separately. RESULTS: Aside from hemangioma and mesenchymal tumors in older adults, no notable changes in survival were observed across the time periods for non-malignant tumors. For malignant brain tumors, significant survival improvements were observed in children with embryonal tumors (logrank p = 0.00028) and in AYA with anaplastic astrocytoma (logrank p = 0.0043). In older adults, significant improvement was observed in the five most common histopathologies except oligodendroglioma. Adjusted for sex, race/ethnicity, and treatment, there were improvements in survival in 2008-2012 and 2013-2017, when compared to 2004-2007, in children and AYA with malignant tumors (Children: HR = 0.92, 95% CI = 0.87-0.98, p = 0.010 in 2008-2012; HR = 0.91, 95% CI = 0.85-0.97, p = 0.005 in 2013-2017; AYA: HR = 0.92, 95% CI = 0.88-0.96, p < 0.001, in 2008-2012; HR = 0.87, 95% CI = 0.83-0.93, p < 0.001 in 2013-2017). CONCLUSIONS: Overall survival for malignant brain and other CNS tumors improved slightly in 2013-2017 for all age groups as compared to 2004-2007. No significant changes were observed for non-malignant brain and other CNS tumors.